Population pharmacokinetics of intravenous ondansetron in oncology and surgical patients aged 1-48 months

European Journal of Clinical Pharmacology

Volumn 66, Issue 1, 2010, Pages 77-86

  Mondick, John T ^a   Johnson, Brendan M ^c   Haberer, Lynda J ^c   Sale, Mark E ^d   Adamson, Peter C ^b   Coté, Charles J ^e   Croop, James M ^f   Russo, Mark W ^c   Barrett, Jeffrey S ^b   Hoke, J Frank ^c  

^a Metrum Institute   (United States)

^b CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^c GLAXOSMITHKLINE   (United States)

^d Next Level Solutions   (United States)

^e MASSACHUSETTS GENERAL HOSPITAL   (United States)

^f INDIANA UNIVERSITY   (United States)

Author keywords

Ondansetron; Pediatric; Population pharmacokinetics

Indexed keywords

ONDANSETRON;

AGE; ALLOMETRY; AREA UNDER THE CURVE; ARTICLE; BODY SIZE; BODY WEIGHT; CANCER PATIENT; CHILD; CLINICAL TRIAL; COMPARTMENT MODEL; CONFIDENCE INTERVAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DISTRIBUTION VOLUME; DRUG CLEARANCE; DRUG HALF LIFE; FEMALE; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; MULTICENTER STUDY; PATIENT MONITORING; PLASMA CONCENTRATION-TIME CURVE; PRESCHOOL CHILD; PRIORITY JOURNAL; SINGLE DRUG DOSE; STATISTICAL ANALYSIS; SURGICAL PATIENT;

ANESTHESIA, GENERAL; ANTIEMETICS; ANTINEOPLASTIC AGENTS; CHILD, PRESCHOOL; COMPUTER SIMULATION; FEMALE; HUMANS; INFANT; INJECTIONS, INTRAVENOUS; MALE; METABOLIC CLEARANCE RATE; NAUSEA; ONDANSETRON; SEROTONIN ANTAGONISTS;

EID: 76949094015     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00228-009-0730-8     Document Type: Article

References (36)

1. JC Bryson JF Pritchard S Shurin AE Kernodle JL Blumer 1991 Efficacy, pharmacokinetics (PK) and safety of ondansetron (OND) in pediatric chemotherapy patients (PTS) Clin Pharmacol Ther 49 2 161
2. IA Spahr-Schopfer J Lerman N Sikich JL Palmer U Jorch 1995 Pharmacokinetics of intravenous ondansetron in healthy children undergoing ear, nose, and throat surgery Clin Pharmacol Ther 58 3 316 321 10.1016/0009-9236(95) 90248-1 1:CAS:528:DyaK2MXpsVSltLo%3D 7554705
3. J Pritchard 1992 Ondansetron metabolism and pharmacokinetics Semin Oncol 19 Suppl 10 9 15 1:CAS:528:DyaK3sXptlKnsw%3D%3D 1387254
4. E Caron JF Bussières D Lebel S Mathews J Milot JL Jacob, et al. 2003 Ondansetron for the prevention and treatment of nausea and vomiting following pediatric strabismus surgery Can J Ophthalmol 38 3 214 222 12733689
5. KD McQueen JD Milton 1994 Multicenter postmarketing surveillance of ondansetron therapy in pediatric patients Ann Pharmacother 28 1 85 92 1:STN:280:DyaK2c7mvFGjtA%3D%3D 8123969
6. PV Smith DS Walton 2001 Prevention of vomiting after general anesthesia for pediatric ophthalmic surgery AANA J 69 1 39 43 1:STN:280: DC%2BD38%2FjtlOksw%3D%3D 11759137
7. SN Khalil AG Roth IT Cohen E Simhi JM Ansermino ME Bolos CJ Coté RS Hannallah PJ Davis PB Brooks MW Russo GC Anschuetz LM Blackburn 2005 A double-blind comparison of intravenous ondansetron and placebo for preventing postoperative emesis in 1- to 24-month-old pediatric patients after surgery under general anesthesia Anesth Analg 101 2 356 361 10.1213/01.ANE.0000155261. 27335.29 1:CAS:528:DC%2BD2MXmtlOmsrw%3D 16037143 (Pubitemid 41045212)
8. ZOFRAN Product Information (2005) GlaxoSmithKline, Research Triangle Park, NC
9. JW Finkelstein 1994 The effect of developmental changes in adolescence on drug disposition J Adolesc Health 15 8 612 618 10.1016/S1054-139X(94)90627-0 1:STN:280:DyaK2M3htVarsQ%3D%3D 7696280
10. JH Rodman 1994 Pharmacokinetic variability in the adolescent: implications of body size and organ function for dosage regimen design J Adolesc Health 15 8 654 662 10.1016/S1054-139X(94)90633-5 1:STN:280: DyaK2M3htVaruw%3D%3D 7696286
11. NJ Bouwmeester BJ Anderson D Tibboel NH Holford 2004 Developmental pharmacokinetics of morphine and its metabolites in neonates, infants and young children Br J Anaesth 92 2 208 217 10.1093/bja/aeh042 1:CAS:528: DC%2BD2cXksl2rsg%3D%3D 14722170 (Pubitemid 38159658)
12. D Hattis G Ginsberg B Sonawane S Smolenski A Russ M Kozlak R Goble 2003 Differences in pharmacokinetics between children and adults-II. Children's variability in drug elimination half-lives and in some parameters needed for physiologically-based pharmacokinetic modeling Risk Anal 23 1 117 142 10.1111/1539-6924.00295 12635728 (Pubitemid 36255427)
13. EV Capparelli 1994 Pharmacokinetic considerations in the adolescent: non-cytochrome P450 metabolic pathways J Adolesc Health 15 8 641 647 10.1016/S1054-139X(94)90631-9 1:STN:280:DyaK2M3htVartQ%3D%3D 7696284
14. AS Rogers 1994 The role of cytochrome P450 in developmental pharmacology J Adolesc Health 15 8 635 640 10.1016/S1054-139X(94)90630-0 1:STN:280: DyaK2M3htVartA%3D%3D 7696283
15. GL Kearns PK Robinson JT Wilson D Wilson-Costello GR Knight RM Ward JN van den Anker 2003 Cisapride disposition in neonates and infants: in vivo reflection of cytochrome P450 3A4 ontogeny Clin Pharmacol Ther 74 4 312 325 10.1016/S0009-9236(03)00225-X 1:CAS:528:DC%2BD3sXnvVyksro%3D 14534518 (Pubitemid 37222852)
16. SN de Wildt GL Kearns JS Leeder JN van den Anker 1999 Glucuronidation in humans. Pharmacogenetic and developmental aspects Clin Pharmacokinet 36 6 439 452 10.2165/00003088-199936060-00005 10427468 (Pubitemid 29317491)
17. S Bryant L Bellamy F Paloucek M Wahl 2003 Acute acetaminophen poisoning in children: kids aren't just little adults J Emerg Med 24 4 472 473 10.1016/S0736-4679(03)00049-0 12745056 (Pubitemid 36555576)
18. M Strolin Benedetti EL Baltes 2003 Drug metabolism and disposition in children Fundam Clin Pharmacol 17 3 281 299 10.1046/j.1472-8206.2003.00140.x 1:CAS:528:DC%2BD3sXltFamurc%3D 12803568 (Pubitemid 36774164)
19. LA Linday 1994 Developmental changes in renal tubular function J Adolesc Health 15 8 648 653 10.1016/S1054-139X(94)90632-7 1:STN:280:DyaK2M3htVarug%3D%3D 7696285
20. LA Linday DE Drayer MA Khan C Cicalese MM Reidenberg 1984 Pubertal changes in net renal tubular secretion of digoxin Clin Pharmacol Ther 35 4 438 446 1:STN:280:DyaL2c7lslGntw%3D%3D 6368090
21. JN van den Anker 1996 Pharmacokinetics and renal function in preterm infants Acta Paediatr 85 12 1393 1399 10.1111/j.1651-2227.1996.tb13942.x 9001646
22. GL Kearns SM Abdel-Rahman SW Alander DL Blowey JS Leeder RE Kauffman 2003 Developmental pharmacology-drug disposition, action, and therapy in infants and children N Engl J Med 349 12 1157 1167 10.1056/NEJMra035092 1:CAS:528:DC%2BD3sXnsV2jtbo%3D 13679531 (Pubitemid 37122329)
23. Beal S, Sheiner BL (1992) NONMEM Users Guide. NONMEM Project Group, University of California at San Francisco
24. DP de Alwis L Aarons JL Palmer 1998 Population pharmacokinetics of ondansetron: a covariate analysis Br J Clin Pharmacol 46 2 117 125 10.1046/j.1365-2125.1998.00756.x 9723819 (Pubitemid 28342781)
25. D Dubois EF Du Bois 1916 A formula to estimate the approximate surface area if height and weight be known Arch Intern Med 17 863 871 1:CAS:528:DyaC28XhtVCnug%3D%3D
26. BJ Anderson AD McKee NH Holford 1997 Size, myths and the clinical pharmacokinetics of analgesia in paediatric patients Clin Pharmacokinet 33 5 313 327 10.2165/00003088-199733050-00001 1:STN:280:DyaK1c%2FltlagsQ%3D%3D 9391745
27. Y Yano SL Beal LB Sheiner 2001 Evaluating pharmacokinetic/pharmacodynamic models using the posterior predictive check J Pharmacokinet Pharmacodyn 28 2 171 192 10.1023/A:1011555016423 1:STN:280:DC%2BD38%2FhtV2htg%3D%3D 11381569 (Pubitemid 33030044)
28. EI Ette 1997 Stability and performance of a population pharmacokinetic model J Clin Pharmacol 37 6 486 495 1:CAS:528:DyaK2sXktlWisbk%3D 9208355
29. EI Ette LC Onyiah 2002 Estimating inestimable standard errors in population pharmacokinetic studies: the bootstrap with Winsorization Eur J Drug Metab Pharmacokinet 27 3 213 224 1:CAS:528:DC%2BD38XnsFemt70%3D 12365204
30. BJ Anderson K Allegaert NH Holford 2006 Population clinical pharmacology of children: modelling covariate effects Eur J Pediatr 165 12 819 829 10.1007/s00431-006-0189-x 16807729 (Pubitemid 44627767)
31. J Alcorn PJ McNamara 2002 Ontogeny of hepatic and renal systemic clearance pathways in infants: part I Clin Pharmacokinet 41 12 959 998 10.2165/00003088-200241120-00003 1:CAS:528:DC%2BD38XotlGisbk%3D 12222995 (Pubitemid 35168438)
32. CM Dixon PV Colthup CJ Serabjit-Singh BM Kerr CC Boehlert GR Park, et al. 1995 Multiple forms of cytochrome P450 are involved in the metabolism of ondansetron in humans Drug Metab Dispos 23 11 1225 1230 1:CAS:528: DyaK2MXpsFKmsr0%3D 8591723
33. AN Edginton W Schmitt B Voith S Willmann 2006 A mechanistic approach for the scaling of clearance in children Clin Pharmacokinet 45 7 683 704 10.2165/00003088-200645070-00004 1:CAS:528:DC%2BD28Xot1eksLs%3D 16802850 (Pubitemid 43990570)
34. T Tateishi H Nakura M Asoh M Watanabe M Tanaka T Kumai S Takashima S Imaoka Y Funae Y Yabusaki T Kamataki S Kobayashi 1997 A comparison of hepatic cytochrome P450 protein expression between infancy and postinfancy Life Sci 61 26 2567 2574 10.1016/S0024-3205(97)01011-4 1:CAS:528:DyaK2sXnslWlur8%3D 9416779 (Pubitemid 28035581)
35. SN de Wildt GL Kearns JS Leeder JN van den Anker 1999 Cytochrome P450 3A: ontogeny and drug disposition Clin Pharmacokinet 37 6 485 505 10.2165/00003088-199937060-00004 10628899
36. M Sonnier T Cresteil 1998 Delayed ontogenesis of CYP1A2 in the human liver Eur J Biochem 251 3 893 898 10.1046/j.1432-1327.1998.2510893.x 1:CAS:528:DyaK1cXhtVKqsr4%3D 9490065